Exploratory Study on LNP-mRNA Drugs Targeting CD19/BCMA for the Treatment of Relapsed and Refractory Autoimmune Diseases

NCT07388212 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

NOT_YET_RECRUITING

Status

27

Enrollment

OTHER

Sponsor class

Conditions

Autoimmune Diseases

Interventions

DRUG: CD19/BCMA in vivo CAR-T

Sponsor

West China Hospital